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Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by bradykinesia, resting tremor, and muscle
rigidity. To date, approximately 50 genes have been implicated in PD pathogenesis, including both Mendelian genes with rare
mutations and low-penetrance genes with common polymorphisms. Previous studies of low-penetrance genes focused on
protein-coding genes, and less attention was given to long noncoding RNAs (lncRNAs). In this study, we aimed to investigate the
susceptibility roles of lncRNA gene polymorphisms in the development of PD. .erefore, polymorphisms (n � 15) of the PINK1-
AS,UCHL1-AS, BCYRN1, SOX2-OT,ANRIL andHAR1A lncRNAs genes were genotyped inHungarian PD patients (n � 160) and
age- and sex-matched controls (n � 167). .e rare allele of the rs13388259 intergenic polymorphism, located downstream of the
BCYRN1 gene, was signiﬁcantly more frequent among PD patients than control individuals (OR� 2.31; p � 0.0015). In silico
prediction suggested that this polymorphism is located in a noncoding region close to the binding site of the transcription factor
HNF4A, which is a central regulatory hub gene that has been shown to be upregulated in the peripheral blood of PD patients. .e
rs13388259 polymorphism may interfere with the binding aﬃnity of transcription factor HNF4A, potentially resulting in ab-
normal expression of target genes, such as BCYRN1.
1. Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disease, which belongs to the group of
motor system disorders. .e key pathological hallmark of
PD is the progressive loss of dopamine-producing cells in the
substantia nigra pars compacta (located in the midbrain),
which results in a dopamine depletion in the striatum. .is
biochemical imbalance manifests with cardinal motor symp-
toms including resting tremor, muscle rigidity, bradykinesia,
and postural instability [1]. PD aﬀects all populations world-
wide with the prevalence of 1-2% among individuals over
65 years of age [2, 3]. Despite the numerous attempts of the
last decades, there is still no known cure for the disease [4].
PD is a genetically heterozygous disease. A small portion of
PD cases is familial, which can be caused by highly penetrant
mutations in Mendelian genes, both with autosomal dominant
(SNCA, LRRK2, VPS35, EIF4G1, and CHCHD2) and with
autosomal recessive (parkin, PINK1, DJ1, ATP13A2, FBXO7,
PLA2G6, and DNAJC) modes of inheritance [5, 6]. Mutations
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in some of these genesmay also play a role in cases that appear to
be sporadic. However, all known monogenic forms of PD ex-
plain only about 30% of familial and 3–5% of sporadic cases [7].
.e sporadic forms of PD are linked to polymorphisms of
low-penetrance genes [6] identiﬁed by case-control studies
and lately in genome-wide association studies (GWAS). .e
single-nucleotide polymorphisms (SNPs) of these suscep-
tibility loci contribute to the development of polygenic
PD forms and are referred as risk variants for the disease.
.e polymorphisms located within common susceptibility
variants—the SNCA, MAPT, LRRK2, GBA, PARK16, BST1,
DGKQ, and STK39 genes—exhibit the strongest association
with sporadic PD [8–11]. .ese previous studies focused on
polymorphisms of protein-coding genes, and little attention
was given to polymorphisms of noncoding genes.
Long noncoding RNAs (lncRNAs), deﬁned as nonprotein-
coding RNA transcripts longer than 200 nucleotides, are
emerging as key regulators of diverse cellular processes [12].
Certain lncRNAs are abundantly expressed in the cells of the
central nervous system, providing an additional regulatory
layer for ﬁne tuning the cellular outcomes necessary for
proper neuronal development and function [13]. Evidence
is accumulating that lncRNAs have a pivotal role in PD
development [14].
.e antisense lncRNA of PINK1 (PINK1-AS) is able to
stabilize the expression of a PINK1 splice variant in neurons
and is involved in mitochondrial biogenesis [15]..e antisense
lncRNA of the UCHL gene (UCHL1-AS) is under the regu-
lation of Nurr1, which is a major transcription factor involved
in dopaminergic cell diﬀerentiation and maintenance [16]. .e
brain cytoplasmic RNA 1 lncRNA (BCYRN1, also referred to as
BC200) gene is predominantly expressed in neural tissues and
shows an elevated level in variety of tumor types [17] and in
Alzheimer’s disease (AD) brain samples [18]. BC200 lncRNA
functions as translation repressor [19]. Another lncRNA im-
plicated in PD is the overlapping transcript (SOX2-OT) of the
SRY-related HMG-box-2 gene (SOX2) which regulates the
cotranscribed SOX2 gene expression in neurogenesis and
serves as a biomarker for neurodegeneration [14, 20]..e highly
accelerated region 1a (HAR1A) gene marks the evolutionary
divergence of humans and chimpanzees and plays a pivotal role
in cortical-neuron speciﬁcation and migration [21]. ANRIL, the
antisense lncRNA of the cyclin-dependent kinase inhibitor 2b
(CDKN2B) gene, is involved in the development of the mel-
anoma and neural system tumor syndrome, familial melanoma
syndrome, and various tumor types; however, its association
with PD has not yet been investigated [22].
Although reported data suggest that lncRNAs regulate gene
expression in the central nervous system, little is known about
the role of their common gene variants in the pathogenesis of
PD..erefore, we aimed to investigatewhether polymorphisms
located in or close to the PINK1-AS, UCHL1-AS, BCYRN1,
SOX2-OT, ANRIL, and HAR1A lncRNA genes are associated
with PD.
2. Patients and Methods
2.1. Investigated Individuals. .e patients (n � 160) partici-
pating in this study were recruited from the Department of
Neurology, University of Szeged, Szeged, Hungary, and from
NEPSY Biobank of the Institute of Genomic Medicine and
Rare Disorders at Semmelweis University, Budapest, Hun-
gary. All patients fulﬁlled the diagnostic criteria for PD.
Patients and age- and sex-matched healthy controls (n � 167)
were of Hungarian ancestry. .e average age was 66.4± 9.31
years for PD patients and 64.9± 8.46 years for healthy con-
trols..e percentage of males was 32.53% for PD patients and
45.50% for controls. .e investigation was approved by the
Internal Ethical Review Board of the University of Szeged and
the Ethical Committee of Semmelweis University. Written
informed consent was obtained from patients and healthy
controls, and the study was conducted according to the
Principles of the Declaration of Helsinki.
2.2. Genotyping. Four lncRNA genes previously implicated
in PD (PINK1-AS (NR_046507), UCHL1-AS (KR709885),
BCYRN1 (NR_001568), and SOX2-OT (NR_075091)) and
two lncRNA genes linked with neuron diﬀerentiation and
migration (ANRIL (AB548314) and HAR1A (NR_003244))
were chosen for genotyping. Polymorphisms selected for
genotypic analysis had not been previously studied in any
neurodegenerative disorders and were present at a high
frequency (global minor allele frequency >0.1) in European
populations..e following 15 lncRNA variations were selected
for analysis: PINK1-AS polymorphisms rs542589, rs1043424,
and rs540038; HAR1A SNPs rs6089838, rs750697, and
rs750696; ANRIL polymorphisms rs10738605 and rs564398;
BCYRN1 SNPs rs10865224 and rs13388259; SOX2-OT poly-
morphisms rs6765739 and rs13096623; and UCHL1 SNPs
rs12649180, rs17443616, and rs2342526.
Genomic DNAwas isolated from peripheral blood samples
using the DNeasy Blood and Tissue Kit (QIAGEN; Hilden,
Germany). Genotyping of the lncRNA polymorphisms was
based on allelic discrimination assays using the TaqMan SNP
Genotyping Assay following the manufacturer’s instructions
(.ermo Fisher Scientiﬁc; Rockford, USA). Each genotyping
plate contained samples genotyped in duplicate across all
plates. ExceptHAR1A rs750696, all SNPs passed quality control
criteria (sample call rate 80%, SNP eﬃciency> 95%, SNP
genotyping accuracy> 99.5%).
2.3. Statistical Analysis. Statistical analysis of PD patients
and controls was carried out according to the guidelines of
case-control allelic association study design. .e statistical
signiﬁcance of the association between the examined SNPs
of the investigated lncRNA genes and PD was determined
with the Fisher exact probability test. .e Bonferroni cor-
rection for the multiple hypothesis of the analyzed SNPs
(n � 14) was also deﬁned. For all SNPs, odds ratios (OR)
with 95% conﬁdence intervals (CI) were also determined. All
statistical analyseswere performedwithVassarStats (http://www.
faculty.vassar.edu/lowry/vassarstats.html).
3. Results
.e 14 polymorphisms passing the quality control criteria
were initially assessed in 101 PD patients and 83 controls
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enrolled at the Department of Neurology and Department of
Dermatology and Allergology, University of Szeged, Szeged,
Hungary. .ree polymorphisms showed promising results
with respect to allele distribution among PD patients and
controls (Supplementary Table 1). .e strongest association
with PD was observed for the BCYRN1 rs13388259 poly-
morphism (OR� 4.43, CI� 2.0–9.8, Fisher exact probability
test p � 0.00004), and notable results were observed for the
SOX2-OT rs6765739 SNP (OR� 1.38, CI� 0.9–2.1, Fisher
exact probability test p � 0.0791) and the UCHL1 rs12649180
SNP (OR� 1.63, CI� 0.9–3.0, Fisher exact probability test
p � 0.0907). No other investigated SNPs exhibited association
with PD with respect to allele distribution in the two groups.
Due to these encouraging initial results, further PD pa-
tients and control individuals were enrolled into the study at
the Department of Neurology, University of Szeged, as well as
at the Institute of Genomic Medicine and Rare Disorders,
Semmelweis University, Budapest, Hungary. .e BCYRN1
rs13388259 SNP, the SOX2-OT rs6765739 SNP, and the
UCHL1 rs12649180 SNP were assessed. For this extended
study group (n � 327; 160 PD patients and 167 healthy
controls), the BCYRN1 rs13388259 SNP again showed strong
association with PD, and its rare allele was signiﬁcantly
more common among PD patients than control individ-
uals (OR � 2.31, CI � 1.3–4.0, Fisher exact probability test
p � 0.0015, Bonferroni correction p � 0.021) (Figure 1).
.e SOX2-OT rs6765739 SNP also showed notable, but not
signiﬁcant diﬀerences in allele distribution between PD
patients and controls (OR � 1.28, CI � 0.9–1.8, Fisher exact
probability test p � 0.0666). .e alleles of the UCHL1
rs12649180 SNP did not exhibit notable diﬀerences in the
distribution in PD patients and controls (Table 1).
.e majority of SNPs are located in noncoding regions
including introns or intergenic regions [23]. .e disease
association of SNPs located in noncoding regions sometimes
is diﬃcult to interpret. Using diﬀerent sources, multiple in
silico analyses were performed to gain information about the
putative functional consequences of the SNP.
According to the Ensembl (http://www.ensembl.org/
index.html), UCSC Genome Browser/SNP 147 (http://www.
genome.ucsc.edu/), VarSome (https://www.varsome.com), and
NCBI/refSNP (https://www.ncbi.nlm.nih.gov/SNP/) databases,
rs13388259 has been assigned the functional class of intron
variant within BCYRN1 (ENSG00000236824.1), whereas
ALFRED (https://www.alfred.med.yale.edu/alfred/index.asp)
and F-SNP (http://www.compbio.cs.queensu.ca/F-SNP) da-
tabase refer to rs13388259 as an intergenic SNP between the
BCYRN1 and EPCAM genes on Chromosome 2. According to
the NCBI/SNP Database, the rs13388259 polymorphism is
located on chr2:47,343,700 (GRCh38)..e diﬀerence between
the predicted functions of the rs13388259 polymorphism
is probably the consequence of the miss-annotation of the
BCYRN1 gene and transcript in various databases. By com-
paring the data in several databases, we found that two over-
lapping genes and their corresponding transcripts have been
given the name BCYRN1 (BC200): a gene 13,458nt in length
(chr2:47,331,060-47,344,517, GRCh38, Gencode Transcript
ENST00000418539.1, and Gencode Gene ENSG00000236824.1)
and a gene 200 nt in length (chr2:47,335,315-47,335,514,
GRCh38, Gencode Transcript ENST00000418539.2, and
Gencode Gene ENSG00000236824); the two genes are in
the same orientation.
To evaluate if the region containing the rs13388259
polymorphism is transcribed, we designed a primer pair for
real-time PCR of that region. Using total RNA isolated from
the peripheral blood of healthy individuals (n � 3) and
chronic lymphoid leukemia (CLL) patients (n � 3), cDNA
reverse transcription was performed followed by a real-time
PCR using the designed primers: no PCR product was de-
tected for the region containing the SNP, although a control
using primers for the GAPDH gene was successful (data not
shown). Using a primer pair designed for the 200 nt tran-
script, a PCR product was obtained in samples derived from
CLL patients but not in samples from healthy controls (data
not shown)..is result is in agreement with previous ﬁndings
that, although BC200 is expressed in normal neural tissue, it is
expressed at higher levels in various tumor types. Based on
this RT-PCR result, we suppose that rs13388259 is located in
an intergenic region.
Results from analysis with the F-SNP software indicated
that the rs13388259 SNP is associated with transcriptional
regulation. TFBIND software (http://www.tfbind.hgc.jp/)
was applied to predict transcription factor binding sites [24],
and the analysis revealed that the single-nucleotide alter-
ation in the rs13388259 region (A/C) possibly modiﬁes the
binding aﬃnity of a putative transcription factor binding site.
To determine the relationships between the identiﬁed SNP
and regulatory sequences, annotations of regulatory elements
containing binding sites were downloaded from the UCSC
genome browser [25]. .e rs13388259 SNP is located 236 bp
downstream of a binding site for the hepatocyte nuclear factor
∗
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Figure 1: Allele distribution of the of the rs13388259 SNP of the
BC200 lncRNA gene among PD patients (n � 160) and controls
(n � 167).
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4 alpha (HNF4A) transcription factor. According to the
ORegAnno DNA regulatory region database, this binding
site might be functionally related to the BCYRN1 gene
(OREG1716976 and OREG1741230) (Figure 2). Further-
more, an enhancer region (ID GH02H047342, localization
chr2:47,342,469-47,347,454) described in the GeneCard
Human Gene Database (http://www.genecards.org) that
regulates both the BCYRN1 and the EPCAM genes is located
near the rs13388259 SNP. .is enhancer region contains
binding sites for transcription factors, including HNF4A.
.e HNF4A transcription factor is associated with gluco-
neogenesis and diabetes and has been identiﬁed as a central
regulatory hub gene upregulated in the peripheral blood of
PD patients [26].
4. Discussion
As human life spans are prolonged, the incidence of neu-
rodegenerative diseases is increasing. PD is the second
most common neurodegenerative diseases worldwide (after
Alzheimer’s disease) and is currently the most important
known risk factor of the elderly with only symptomatic
treatment [2, 3]. .erefore, insight into the mechanism of PD
is essential. In this study, we contribute to the understanding
of the putative roles of lncRNAs, which provide an additional
level of gene expression regulation in the development of
sporadic, polygenic PD.
We compared the distribution of the rare and wild-type
alleles of 15 polymorphisms of the PINK1-AS, UCHL1-AS,
BCYRN1, SOX2-OT, ANRIL, and HAR1A lncRNA genes in
Hungarian PD patients and ethnicity-, age-, and sex-matched
controls. Our results demonstrated strong association be-
tween the presences of the rs13388259 intergenic poly-
morphism and PD..is intergenic SNP is located between the
BCYRN1 and EPCAM genes on Chromosome 2, and a
functional link to BCYRN1 has been annotated for the region
(http://www.varsome.com, http://www.noncode.org).
.e BCYRN1 lncRNA gene arose after the separation
of monkeys and humans in the mammalian linage as
a consequence of the recruitment of the monomeric Alu
element, which was subjected to retro transposition from an
active master gene 35–55 million years ago [27, 28]. BC200 is
primate tissue-speciﬁc RNA polymerase III transcript [29]
exhibiting brain-speciﬁc expression in transgenic mice [30].
.e BC200 lncRNA is involved in local translational control
[31, 32]. Dysfunction of the BC200 lncRNA in neurons—due to
either altered expression or mislocalization—results in the
deregulation of dendritic mRNA expression, failure of long-
term synaptic plasticity, and thus, neurodegeneration
[14, 18, 33].
.e BCYRN1 lncRNA listed as a 200 nt transcript in
the Ensemble Genome Browser (ID: ENST00000418539.2,
http://www.ensemble.org) [34]. .e rs13388259 SNP is located
within an untranscribed region downstream of the BC200
lncRNA and replaces adenine with cytosine (NG_012352.2:
g.3538A>C). A binding site for the HNF4A transcription factor
is located 236nt upstream of the SNP, and a short interspersed
nuclear element (AluSx) is located 73nt downstream.
.eminor allele frequency (MAF) for the cytosine variant
is 0.0865 in the European and in the American population
and 0.1807 in Africans. No known clinical signiﬁcance of this
polymorphism has previously been identiﬁed by GWAS
studies of PD or any other disease.
Previous studies have conﬁrmed that genetic variants in the
primary sequence of the lncRNA genes (noncoding RNA
transcripts) are highly correlated with human diseases [35, 36].
However, it is diﬃcult to determine the contribution of intronic
and intergenic SNPs to the development of disease since these
are located outside of the primary RNA sequences. .e ex-
pression pattern of many lncRNAs shows spatial and temporal
speciﬁcity, pointing to the strong regulation of lncRNAs
expression [37]. Abnormal expression of several lncRNAs
is linked to human diseases, for example, elevated level of
particular lncRNAs expression closely correlates with
several types of cancer formation and/or metastatic activity
[38, 39]. SNPs of noncoding genomic regions—either
intronic or intergenic—are often located in or closely
linked to regulatory regions [23]. .ey may interfere with
host regulatory elements [40, 41] andmay aﬀect the expression
Table 1: Genotype and allele distributions of the rs13388259 SNP of the BC200 lncRNA gene, the rs6765739 SNP of the SOX2-OT lncRNA
gene, and the rs12649180 SNP of the UCHL1 lncRNA gene in PD patients (n � 160) and controls (n � 167).
Genotypes (n) Alleles (n) Statistical analysis
Homozygous
wild type Heterozygous
Homozygous
rare
Wild
type Rare
Odds
ratio
95%
conﬁdence
interval
Fisher exact
probability
test
rs13388259 SNP of the BC200 lncRNA gene
PD patients
(n � 160) 117 43 0 277 43 2.31 1.3–4.0 p � 0.0015
Controls (n � 167) 147 19 1 313 21
rs6765739 SNP of the SOX2-OT lncRNA gene
PD patients
(n � 160) 17 139 4 173 147 1.28 0.9–1.8 p � 0.0666
Controls (n � 167) 35 131 1 201 133
rs12649180 SNP of the UCHL1 lncRNA gene
PD patients
(n � 160) 126 34 0 287 34 1.21 0.8–2.0 p � 0.2516
Controls (n � 167) 125 42 0 292 42
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level of lncRNAs implicated in the pathogenesis of certain
diseases..e results of our in silico analysis demonstrated that
the BCYRN1 rs13388259 polymorphism lies close to the
binding site of the transcription factor HNF4A. HNF4A was
identiﬁed as a central regulator hub gene upregulated in
peripheral blood of PD patient [42]; moreover, the relative
abundance of the HNF4A mRNA correlates with the severity
of the disease: upon 3-year follow-up constantly increasing
HNF4A expression was observed [26]. .e BCYRN1 was
predicted as a target gene of HNF4A transcription factor
binding site. .ese data together suggest that the rs13388259
polymorphism may modify the expression level of BC200
lncRNA due to the modiﬁcation of HNF4A transcription
factor binding aﬃnity.
Previous studies linked BC200 lncRNA with neuro-
degeneration [18, 36]. .is is the ﬁrst study, however, which
conﬁrms the genetic association between the genomic
context of the BCYRN1 lncRNA gene and PD. Our study
further emphasizes the increasing awareness of the sig-
niﬁcance of lncRNAs in the development of human dis-
eases. Further studies are needed to conﬁrm the functional
relevance of the identiﬁed genetic variants in the expression
and/or activity of the BC200 lncRNA and its functions in
dopaminergic neurons.
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